About Cyfuse
Cyfuse is a company based in Bunkyo (Japan) founded in 2010. Cyfuse has raised $16.56 million across 2 funding rounds from investors including Shibuya Kogyo, m3.com and Cyberdyne. The company has 21 employees. Cyfuse operates in a competitive market with competitors including Nuclera Nucleics, CELLINK, Aspect Biosystems, OxSyBio and Collplant, among others.
- Headquarter Bunkyo, Japan
- Employees 21
- Stage Public
- SectorsHealthcareTechnology
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website cyfusebio.com
- Social LinkedIn Instagram
- Legal Name Cyfuse Biomedical K.K.
- Annual Revenue$1.47 M (USD)324.27as on Dec 31, 2025
- Net Profit-$4.88 M (USD)12.43as on Dec 31, 2025
- EBITDA-$5.06 M (USD)7.84as on Dec 31, 2025
- Total Equity Funding$16.56M (USD)
in 2 rounds
- Latest Funding Round$11.76M (USD), Series B
Feb 2015
- InvestorsShibuya Kogyo
& 11 more
- Employee Count21
Funding Insights of Cyfuse
Cyfuse has successfully raised a total of $16.56M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $11.76 million completed in February 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.56M
- Total Rounds 2
- Last Round Series B — $11.76M
- First Round $4.8M
(Jan 2013)
- Investors Count 12
All 2 funding rounds of Cyfuse with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2015 | $11.76M | Series B | – | Cyberdyne, Shibuya Kogyo | |
| Jan 2013 | $4.8M | Series A | – | UTEC |
12 investors in total: 12 institutional.
Investors in Cyfuse
Cyfuse has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Shibuya Kogyo, m3.com and Cyberdyne.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and Early stage VC firm investing in Japan | – | ut-ec.co.jp | Tokyo, Japan | |
Venture capital services are provided to support startups and innovation. | – | daiwa-inv.co.jp | Tokyo, Japan | |
Venture capital investments are provided to innovative startups by DBJ Capital. | – | dbj-cap.jp | Japan | |
VC firm investing in Japan and the US | – | nvcc.co.jp | Chiyoda City, Japan | |
Venture capital firm investing in biotech, adtech sectors | – | nissay-cap.co.jp | Chiyoda City, Japan | |
Venture capital is invested in AI, energy, and various sectors. | – | mucap.co.jp | Tokyo, Japan | |
Develops robotic assistive technology and commercial cleaning robots | 2004 | cyberdyne.jp | Tsukuba, Japan | |
Medical devices for biological 3D tissue printing are produced. | 1931 | shibuya.co.jp | Kanazawa, Japan | |
Buyouts are targeted through venture capital and private equity investments. | – | jafco.co.jp | Minato City, Japan | |
Japan's members-only networking site for healthcare professionals is operated. | 2000 | m3.com | Tokyo, Japan |
Investor details for Cyfuse
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cyfuse
1 people are tracked at Cyfuse (1 in leadership); the tracked headcount is 21.
| Name | Role | Group |
|---|---|---|
Shizuka Akieda | CEO | Leadership |
Complete people profiles for Cyfuse
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Cyfuse
Cyfuse is a publicly listed company on the TSE with ticker symbol 4892 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Dec 2022
- Listed onTSE: 4892
- Listed entityCyfuse Biomedical K.K.
- Exchange sectorHealth technology
- ISINJP3311800001
- Share price622.00 JPY (+1.63% on the day) · 2026-10-09
- Market capitalisation6,176,364,704.00 JPY
- EPS (diluted, trailing year)-82.47 JPY
- Volume (last session)38,400
Financials of Cyfuse
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 231.0M JPY | -763.8M JPY | -792.7M JPY |
| 2024 | 54.5M JPY | -872.2M JPY | -860.1M JPY |
| 2023 | 61.1M JPY | -589.2M JPY | -659.3M JPY |
| 2022 | 374.5M JPY | -474.0M JPY | -370.8M JPY |
| 2021 | 708.2M JPY | 142.9M JPY | 89.1M JPY |
Detailed financial statements for Cyfuse
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Cyfuse
4 dated milestones of Cyfuse across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Cyfuse is founded.
- Funding First funding round of $4.8M.
- Funding Latest funding round, Series B, of $11.8M.
- IPO Lists on the stock exchange (IPO).
Competitors of Cyfuse
Cyfuse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuclera Nucleics, CELLINK, Aspect Biosystems, OxSyBio and Collplant, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nuclera.com | 2013 | Cambridge, United Kingdom | $164.2M | 134 | Desktop bioprinter for genes and proteins production is developed. | |
| cellink.com | 2016 | Boston, United States | – | 65 | 3D bioprinters and bioinks are developed for research applications. | |
| aspectbiosystems.com | 2013 | Vancouver, Canada | $138.68M | 49 | Bioprinting technology and tissue therapeutics for regenerative medicine are developed. | |
| oxsybio.com | 2014 | London, United Kingdom | $16.35M | 285 | Provider of 3D printing of tissue biomaterials for medical research and clinical applications | |
| collplant.com | 2004 | Ness Ziona, Israel | $16.3M | – | Plant-derived collagen is developed for tissue repair and 3D bioprinting. | |
| precise-bio.com | 2015 | Winston-salem, United States | $12M | 6 | Developer of integrated 3D printing and tissue-engineering platform | |
| rokithealthcare.com | 2012 | Seoul, South Korea | $9.85M | – | 4D bio-printer solutions for tissue regeneration are provided. | |
| bico.com | 2016 | Boston, United States | – | 955 | Technologies, products, and services for life sciences research are provided. | |
| triastek.com | 2015 | Nanjing, China | $102.3M | – | Provider of 3D printing pharmaceutical technology platform for drug design | |
| inventia.life | 2013 | Sydney, Australia | $41M | – | Developer of 3D bio-printers |
Detailed competitors of Cyfuse
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cyfuse
The website of Cyfuse (cyfusebio.com) receives about 5.4K visits a month and ranks #2,997,368 among all websites worldwide, #3,977 in Biotechnology and Pharmaceuticals.
- Monthly visits5.4K
▼ 5.7% vs previous month
- Unique visitors1.9K
per month
- Global rank#2,997,368
among all websites
- Category rank#3,977
Health · Biotechnology and Pharmaceuticals
- Bounce rate51%
- Pages per visit2.6
- Average visit2 min 12 sec
- DevicesDesktop 55% · Mobile 45%
Websites whose visitors overlap most with Cyfuse. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| firm.or.jp | 100% | – | #1,593,377 | View details | |
| slil.com | 92% | – | – | View details | |
| chronixbiomedical.com | 92% | – | – | View details | |
| biomedsys.com | 58% | – | – | View details | |
technologies-biomedicales.com | technologies-biomedicales.com | 58% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Cyfuse
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Cyfuse
Complete news archive for Cyfuse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cyfuse
10 companies that operate in the same segment as Cyfuse (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cyfuse
Cyfuse was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Cyfuse is headquartered in Bunkyo, Japan. It is registered at Bunkyo, Tokyo, Japan.
Shizuka Akieda is the current CEO of Cyfuse.
Cyfuse is a funded company, having raised a total of $16.56M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4.8M, raised on Jan 2013.
Cyfuse has 21 employees.
Annual revenue of Cyfuse is $1.47M as on Dec 31, 2025.
Founded in 2010 and based in Bunkyo, Japan, Cyfuse focuses on the biotechnology sector through 3D bioprinters. The Regenova system is utilized for producing three-dimensional tissues and organs, while the Spike device is employed to assemble spheroids into custom shapes. These tools support advancements in regenerative medicine and drug discovery processes. Operations emphasize automated fabrication to aid research and development in tissue engineering.
Cyfuse's top competitors include Nuclera Nucleics, Aspect Biosystems and Collplant.
Yes, Cyfuse is publicly traded on TSE under the ticker symbol 4892.
Cyfuse has 12 investors. Key investors include Shibuya Kogyo, m3.com, Cyberdyne, UT-EC Japan, and JAFCO Group.